The authors added that the adoption of this technology in hospitals has already improved the manner in which healthcare practitioners detect and monitor KRAS, BRAF, and EGFR mutations in patients with lung, colon, and breast cancer, respectively [14]. This evidence concerns the gene KRAS and breast carcinoma.